Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
Date:7/30/2009

PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and six months ended June 30, 2009.

Financial Highlights

  • Adjusted diluted EPS, which excludes the impact of certain purchase accounting items as well as other non-cash and/or non-recurring items as detailed below, was $0.32 and $0.65 for the three and six months ended June 30, 2009, compared to $0.20 and $0.29 for the same prior year periods;
  • Total revenues of $1.27 billion for the three months ended June 30, 2009, an increase of $63.9 million over the same prior year period;
  • Total revenues of $2.48 billion for the six months ended June 30, 2009, an increase of $199.3 million over the same prior year period;
  • On a GAAP basis, the company reported diluted EPS of $0.19 and $0.42 for the three and six months ended June 30, 2009, compared to a loss per share of $0.05 and $1.52 in the same prior year periods. The six months ended June 30, 2008 included a non-cash goodwill impairment charge of $385.0 million related to the Specialty Segment.

Mylan's Chairman and CEO Robert J. Coury commented: "This was yet another successful quarter on many fronts for Mylan as, across the board, we delivered another quarter of financial performance that exceeded our expectations. Our powerful and integrated global platform enabled each of our businesses to generate year-over-year quarterly revenue growth on a constant currency basis and to deliver additional operational efficiencies as well. In addition, we took an important initial step in one of our targeted areas of future growth by entering into a collaborative agreement with Biocon in the area of generic biologics."


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
2. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
3. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
4. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
5. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
6. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
7. Mylan Confirms Four First-to-File Challenges
8. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
9. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
10. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and NEW ORLEANS , ... in the field of regenerative medicine, presented new data ... from Analysis Group (a leading health economics consultancy) demonstrating ... foot ulcers (DFU) and venous leg ulcers (VLU) place ... results of this research, which reveal annual costs of ...
(Date:5/22/2013)... Toronto, Ontario (PRWEB) May 22, 2013 ... of advanced sound therapy for tinnitus treatment. AudioNotch ... Destination Hearing . With clinic locations in both ... trusted provider of audiology and hearing services. AudioNotch's ... Zabell locations. , Upon entering a Destination Hearing ...
(Date:5/22/2013)... 2013 Alton Housing Authority was hit by ... said that their presence has already caused the company ... avoid such big spending, My Cleaning Products shared a way ... was said in the report that to clear the ... from that, its employees also attended a mandatory training on ...
(Date:5/22/2013)... May 22, 2013 The ability ... deciphering the information they encode. There are now ... (deep sequencing of ribosome protected fragments) that dramatically ... , Keynote speakers include Dr. Jonathan Weissman, an ... the Howard Hughes Medical Institute, who will present ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2
... Cynvec LLC, a privately-held,biopharmaceutical company focused on developing ... the Sindbis viral vector, announced today,that it has ... effective immediately, to lead the company,s next phase ... Mr. Stonebanks will serve on Cynvec,s Board,of Directors., ...
... , - Revenues Expected to be up 26%, ... Site Limited ("The Binding Site" or the "Company"), a,privately-owned ... the year ended 30th September 2008. The full audited,results ... are expected to be GBP38.9 million, representing sales growth,of ...
... - Fourth quarter constant currency revenue growth of 12.9 ... percent, constant currency), and improving profitability reflects ... annual financial guidance for fiscal year 2009, BATESVILLE, ... ), announced unaudited financial results for its fiscal,fourth quarter ...
Cached Biology Technology:Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 2Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 3The Binding Site Announces Trading Update for Year Ended September 30th 2008 2The Binding Site Announces Trading Update for Year Ended September 30th 2008 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19
(Date:5/21/2013)... the path of insulin action in cells in precise ... for understanding what goes wrong in diabetes. , ... David James from Sydney,s Garvan Institute of Medical Research, ... the prestigious journal Cell Metabolism . , First ... important role in the body because it helps us ...
(Date:5/20/2013)... University of Minnesota Medical School researchers from the Masonic ... University,s Brain Tumor Program, have developed a new mouse ... allow them to discover new genes and gene pathways ... published this week in the journal Nature Genetics ... in the lab of David Largaespada, Ph.D., professor in ...
(Date:5/20/2013)... URBANA - A National Science Foundation (NSF) planning grant ... Drying (CARD), a joint program of the University of ... Worcester, Mass. , "CARD will be devoted to research ... other agricultural products; forestry and paper products; chemical products; ... I professor of food science and human nutrition and ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2
... WEST LAFAYETTE, Ind. - Bacteria are ... and cause disease - by manipulating a natural cellular process. , ... team that revealed how a pair of proteins from the bacteria ... protein in order to divert raw materials within the cell for ...
... Sweden, have used advanced light microscopy to show that a ... what it is mixed with. This may determine whether it ... able to identify specific cells and proteins in the skin ... understanding of the mechanisms behind contact allergy", says Carl Simonsson ...
... Scientists studying a unique collection of human skulls have ... have occurred independently through separate evolutionary events may have ... of Manchester and Barcelona examined 390 skulls from the ... human skull is highly integrated, meaning variation in one ...
Cached Biology News:Purdue scientists reveal how bacteria build homes inside healthy cells 2Purdue scientists reveal how bacteria build homes inside healthy cells 3Interactions between substances determine allergenic potential 2Human skull study causes evolutionary headache 2
... An antibody made to the C-terminal VMAT2 ... kDa in postnuclear supernatants of CHO transfected ... cells (2). Some additional bands, both higher ... and remain unaffected by the inclusion of ...
... Metalloproteinase-2, Hinge Region By immunoblotting the antibody ... It reacts with free MMP-2 or MMP-2 ... buffered aqueous glycerol solution Solution in ... containing 50% glycerol and 15 mM sodium ...
Acetylcholinesterase from human and monkey....
...
Biology Products: